Research programme: signal transduction pathway inhibitors - Mercury Therapeutics
Latest Information Update: 10 Apr 2007
At a glance
- Originator Mercury Therapeutics
- Class Small molecules
- Mechanism of Action Ras signal transduction pathway inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 10 Apr 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
- 05 Dec 2002 Mercury Therapeutics has acquired exclusive worldwide rights to a drug target from Massachusetts General Hospital
- 26 Sep 2002 Preclinical trials in Cancer in USA (unspecified route)